Censo
Censo Bio is a specialist contract research organization focused on complex cell biology for human neurodegenerative and neuroinflammatory disease research, serving biotech and pharmaceutical sponsors with advanced cell-based assay services.
- Company typePrivate
- Founded2016
- HeadquartersMidlothian, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Censo firmographics
Firmographics- Name
- Censo
- Website
- https://censobio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Censo Bio is a specialist contract research organization focused on complex cell biology for human neurodegenerative and neuroinflammatory disease research, serving biotech and pharmaceutical sponsors with advanced cell-based assay services.
- Ownership category
- akta.pro rank
Censo industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
Keywords
Where Censo is headquartered
LocationHeadquarters
- HQ city
- Midlothian
- HQ country
- United States
- HQ region
- North America
Markets served
Censo business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Censo product offering
Product offeringCore offering
Censo Bio is a specialist contract research organization providing complex cell biology research services with focused expertise in human neurodegenerative and neuroinflammatory disease models. The company supports preclinical drug discovery efforts for biopharmaceutical and academic clients through specialized cell-based assay and disease model research.
Differentiator
Problem solved
Functional benefit
Products and services
- Neurodegenerative Disease Cell Biology Research Services Specialist contract research services applying complex cell biology techniques to human neurodegenerative disease models, supporting preclinical drug discovery for biopharmaceutical and academic clients.
- Neuroinflammatory Disease Cell Biology Research Services Specialist contract research services applying complex cell biology techniques to human neuroinflammatory disease models, supporting preclinical drug discovery for biopharmaceutical and academic clients.
Companies that use Censo
Customer profileIdeal customer profiles1 record
Censo technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Censo competitors and assessment
Company assessmentBroad incumbents
- WuXi AppTec: Global CRO/CDMO offering preclinical biology, cell-based assays, and neuroscience services. Comparable as a broad incumbent serving similar customer types (biopharma discovery teams).
- GenScript ProBio: Global life sciences services provider offering cell biology, gene synthesis, and preclinical biology services. Comparable in cell biology CRO services though broader in scope.
- Evotec: Global discovery and preclinical CRO with extensive neuroscience and cell biology service lines. Represents the scaled version of the same operating model Censo occupies at smaller scale.
- Charles River Laboratories: Large global CRO with significant discovery, cell biology, and CNS preclinical services. Overlaps with Censo's capabilities as a broad incumbent in the same service categories.
- Eurofins Discovery: Division of Eurofins Scientific offering cell biology, pharmacology, and disease-model services including CNS models. Overlapping services and customer base.
- Aptuit (an Evotec company): Integrated drug discovery CRO with strong CNS and cell biology capabilities, now part of Evotec. Provides benchmark for what scaled-up specialty CROs look like after acquisition.
Direct peers
- BioAscent Discovery: Scotland-based drug discovery CRO offering medicinal chemistry, biology, and in vitro pharmacology. Geographic and scale peer operating from the same UK life sciences cluster.
- Sygnature Discovery: UK-based preclinical CRO with strong neuroscience and cell biology capabilities. Highly comparable in scale, therapeutic focus, and geographic ecosystem to Censo.
- reMYND: Specialized CRO focused on neurodegenerative disease models (Alzheimer's, Parkinson's, diabetes) with cell biology and in vivo capabilities. Closely comparable therapeutic-area focus to Censo.
Emerging players
- Qx Therapeutics: Specialized preclinical CRO focused on CNS drug discovery and disease modeling. Direct niche overlap with Censo's neurodegenerative focus at similar early-stage scale.
Market position
Customer concentration
Censo social profiles
Digital presenceCenso financial estimates
Financial estimateRevenue estimate
Valuation estimate
Censo leadership team
Management profileNumber of profiles
Profiles1 record
Censo funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Censo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Censo
What does Censo do?
Censo Bio is a specialist contract research organization providing complex cell biology research services with focused expertise in human neurodegenerative and neuroinflammatory disease models. The company supports preclinical drug discovery efforts for biopharmaceutical and academic clients through specialized cell-based assay and disease model research.
Is Censo a public or private company?
Censo is a private company. It is classified as venture growth investor backed and is currently operating.
When was Censo founded?
Censo was founded in 2016. It employs 11 to 50 people.
Where is Censo based?
Censo is headquartered in Midlothian, United States, in the North America region.
Who are Censo's main competitors?
Broad incumbents on record are WuXi AppTec, GenScript ProBio, Evotec, Charles River Laboratories, Eurofins Discovery and Aptuit (an Evotec company). Direct peers are BioAscent Discovery, Sygnature Discovery and reMYND. Qx Therapeutics is listed as an emerging player.
Does Censo have an API?
No public API is recorded for Censo.
What industry is Censo in?
Censo's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 541714 and its SIC code is 8731.